[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"myocardial-bridge\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:myocardial-bridge":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100582017","myocardialbridge-bypass-graft-surgery-efficacy-verification-100582017",false,"NCT06857838","Myocardialbridge Bypass Graft Surgery Efficacy Verification","Inclusion Criteria:\n\n* Patients with myocardialbridge requiring drug therapy or surgical intervention.\n\nExclusion Criteria:\n\n* patients with myocardialbridge not requiring drug therapy or surgical intervention, or unwilling to be enrolled for any reason","ALL","18 Years","80 Years",{"count":19,"type":20},500,"ESTIMATED","INTERVENTIONAL",[23],"NA","Myocardial Bridge Bypass Graft surgery is introduced to relieve the unmedical symptoms of patients with long-segment or deep myocardial bridge, clinical outcomes will be collected to verify the effectiveness of the surgery.",[26,27,28,29,30,31,32,33,34,35],"Myocardial Bridge of Coronary Artery","Myocardial Bridge","Myocardial Bridging","Myocardial Infarction","Myocardial Ischemia","Pectoris, Stable Angina","Sudden Cardiac Death","Bypass Graft Stenosis","Bypass Graft Occlusion","Bypass Graft Thrombosis","RECRUITING","2025-02-26",{"date":39,"type":40},"2025-03-04","ACTUAL",{"date":42,"type":40},"2020-01-01",{"date":44,"type":20},"2040-12-31",{"name":46,"class":47},"Xi'an International Medical Center Hospital","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":21,"phases":59,"briefSummary":60,"conditions":61,"keywords":62,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100537687","reassessment-of-myocardial-bridge-towards-personalized-medicine-100537687","NCT06281067","Reassessment of myocardIAL Bridge TOwards PeRsOnalized Medicine","Reassessment of myocardIAL Bridge TOwards PeRsOnalized Medicine: RIALTO PRO","RIALTO PRO","Inclusion Criteria:\n\n1. Ability to give informed consent to the study.\n2. Age ≥ 18 years and ≤ 75 years.\n3. Diagnosis of MB during index coronary angiography\\*.\n4. Symptoms or signs of inducible ischemia (if signs, these should involve the territory of the index vessel).\n\nAngiographic definition of MB \\*\n\nMyocardial bridge is a congenital anomaly characterized by an intramural course of an epicardial coronary segment. This anatomical arrangement causes the artery to be squeezed during systole, with a relaxation in diastole. In this study, MB is defined as a visual ≥ 50% reduction in the minimal luminal diameter during systole and a complete or partial relaxation in diastole (\"milking effect\").\n\nThe use of intracoronary vasodilators (i.e., nitrates) can increase the systolic narrowing of the vessel, through a reflex rise of the adrenergic drive, and consequently the angiographic sensitivity in detecting MB.\n\nExclusion Criteria:\n\n1. Moderate to severe CAD (≥ 50% stenosis in any vessel, including chronic total occlusion) at the time of enrolment\u002Frandomization.\n2. Previous CABG involving the index vessel.\n3. Severe valvular heart disease.\n4. Left ventricular systolic dysfunction \\[ejection fraction (EF) \\\u003C 40%\\], regardless of the etiology.\n5. Clinically significant right ventricular dysfunction.\n6. Known severe renal impairment (eGFR \\\u003C 30 ml\u002Fmin\u002F1.73 m2).\n7. Known severe hepatic impairment, or history of cirrhosis with evidence of portal hypertension.\n8. History of malignancy of any organ system with a life expectancy \\\u003C 1 year.\n9. Any previous history of ischemic stroke, intracranial haemorrhage or disease (neoplasm, arteriovenous malformation, aneurysm).\n10. Pregnant or breastfeeding women.\n11. Known hypersensitivity or contraindication to any of the drugs used for coronary physiology testing (nitrates, adenosine, dobutamine, acetylcholine).","75 Years",{"count":19,"type":20},[23],"The \"RIALTO-PRO\" study aims to optimize the diagnostic and therapeutic algorithm for myocardial bridge (MB) patients, testing the diagnostic value of a full invasive diagnostic procedure, and, consequently, the prognostic value of a tailored approach. the study objective is to determine the diagnostic and prognostic value of a full-physiology approach strategy versus a standard approach strategy in patients with a MB.\n\nThe \"RIALTO PRO\" study is a randomized, multicentre, prospective, open-label, superiority trial comparing a personalised versus standard management in patients with MB. Consenting and eligible patients will be randomised 1:1 to either a \"full-physiology approach\", consisting of a comprehensive diagnostic algorithm aimed at unmasking the main pathophysiological mechanism of myocardial ischemia and consequently a tailored treatment, or a \"standard approach\", consisting of angiographic evaluation of the tunnelled segment.",[27],[63,64],"myocardial bridge","Personalized Medicine","2024-07-09",{"date":67,"type":40},"2024-07-10",{"date":69,"type":40},"2023-12-15",{"date":71,"type":20},"2026-01-01",{"name":73,"class":47},"Azienda Ospedaliero Universitaria Maggiore della Carita",34]